Patients suffering from chronic thromboembolic pulmonary hypertension (CTEPH) or recurrent CTEPH in Wales now have access to Bayer’s therapy Adempas (riociguat) — a soluble guanylate cyclase (sGC) stimulator that works by relaxing blood vessels and increasing the supply of blood to the lungs, which helps reduce the workload of the heart. The All Wales Medicines…

October 13 is World Thrombosis Day, an event that increases global awareness and focuses attention on the often overlooked and misunderstood disease of thrombosis as an urgent and growing health problem. In recognition of World Thrombosis Day and the seriousness and prevalence of venous thromboembolism (VTE), the Montreal,…

According to an article entitled “Mosaic Pattern of Lung Attenuation on Chest CT in Patients with Pulmonary Hypertension”  published in the journal Disease on September 7, 2015 and authored by Kamonpun Ussavarungsi et al., a mosaic lung attenuation pattern can be observed in the chest…

The Pulmonary Hypertension Association (PHA) is currently hosting the 2015 PH Professional Network (PHPN) Symposium, which began on Thursday, September 17 and will run until Saturday, September 19 at the Crystal Gateway Marriott in Arlington, Va. Invited to give an inspiring and insightful talk on her story as a PH patient is Pam Kehoe,…

Patients with pulmonary hypertension may be surprised to know that the disease can sometimes be accompanied by the complication known as thromboembolic pulmonary hypertension (CTEPH). Pulmonary embolisms are the root cause of CTEPH because a pulmonary embolism (a blood clot in the lungs) that fails to be degraded via thromboembolysis…

As the supplier of the body’s blood, the heart must also supply its own blood to keep itself nourished and oxygenated. The heart’s blood supply comes from the coronary arteries, which receive oxygenated blood from the pulmonary veins. Normally, the heart receives enough oxygenated blood, but with chronic thromboembolic pulmonary hypertension (CTEPH)…

Understanding the science behind chronic thromboembolic pulmonary hypertension (CTEPH) has come a long way since, originally, a diagnosis was made postmortem. Although it is commonly underdiagnosed and undertreated, CTEPH can be cured via pulmonary endarterectomy (PEA), a technique that dates back almost to the first diagnosis of CTEPH. “At the…

Bayer HealthCare will deliver six presentations at the ongoing American Thoracic Society (ATS) International Conference in Denver, Colorado. Five posters and one oral presentation will describe data concerning treatment of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). “At the American Thoracic Society…

Patricia Middings of Chester, N.J., is the winner of “Breathless Moments,” a photo contest launched by Bayer in order to raise awareness for chronic thromboembolic pulmonary hypertension (CTEPH). The idea of the challenge was to portray inspirational moments, events or sights that leave someone breathless. Contest judges Trace Cluck,…

Bellerophon Therapeutics, Inc., a clinical-stage biotherapeutics company, recently announced the formation of a Scientific Advisory Board (SAB) for its INOpulse technology that includes internationally recognized experts in the field of pulmonary hypertension (PH). The SAB will work closely with Bellerophon’s medical team while the firm prepares to further the advancement of its proprietary inhaled…

A lot can change in five years, especially when someone has chronic thromboembolic pulmonary hypertension (CTEPH). A group of doctors at the University of Würzburg and Katharinen-Hospital Unna in Germany followed a 68-year-old woman for five years, from the time of her visiting the clinic with shortness of…